Clinical trial · Interventional
Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer
Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer
NCT00883675CI-TRIAL-00013032completedPhase 4Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether it is safe to treat lung cancer patients who have undergone an attempt at curative resection with the combination of docetaxel and carboplatin.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Docetaxel-Carboplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment
- description
- Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin Area Under the Curve 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses
- interventionNames
- Drug: Docetaxel-Carboplatin
Primary outcomes (1)
- measure
- Febrile Neutropenia
- timeFrame
- 2 months
- description
- The primary endpoint of the study was safety, as reflected by a febrile neutropenia rate of \<10%.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Non-small cell lung cancer stage IB - IIIA, complete resection with mediastinal lymph node dissection * ECOG status 0-1 * \>14 and \<56 days since resection Exclusion Criteria: * Prior chemotherapy and/or radiation therapy for lung cancer * Peripheral neuropathy \> grade 1 * Concurrent other malignancies, other than basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix * Medical condition that will not permit treatment or follow up according to the protocol * Prior treatment with docetaxel or carboplatin * Hypersensitivity to polysorbate 80, platinum-containing compounds or mannitol * Treatment with other investigational anti-cancer drugs within 30 days of registration * Pregnant or nursing women * HIV-positive patients
References
Publications (1)
- DERIVEDZhi X, Gao W, Han B, Yang Y, Li H, Liu D, Wang C, Min G, Long H, Rigas JR, Carey M, Jahan T, Sammann A, Reza J, Wang D, Mann MJ, Jablons DM, He J; China Clinical Trials Consortium. VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer. J Thorac Dis. 2013 Oct;5(5):578-84. doi: 10.3978/j.issn.2072-1439.2012.02.05. PMID 24255769